Roche Opens Institute of Human Biology – CHF 1.4 Billion Basel Investment Targets Human Model Systems for Drug Discovery Revolution
Roche (SWX: ROG, OTCMKTS: RHHBY) announced the inauguration of the new research home for the...
OTCMKTS: RHHBY
Roche Deploys 2,176 NVIDIA GPUs in Global AI Factory – Largest Pharma GPU Footprint Expands to 3,500+ Blackwell Units
Roche (SWX: ROG, OTCMKTS: RHHBY) announced the expansion of its global AI infrastructure through the...
Roche’s Petrelintide Hits 10.7% Weight Loss in Phase II ZUPREME-1 Trial – Amylin Analog Shows Sustained Efficacy Through Week 42
Roche (SWX: ROG, OTCMKTS: RHHBY) announced positive topline results from the Phase II ZUPREME-1 trial...
Roche’s Xofluza Wins NMPA Approval for Pediatric Expansion – Oral Suspension Cleared for Children Under 5 Years
Roche (SWX: ROG, OTCMKTS: RHHBY) announced that Xofluza (baloxavir marboxil) has received expanded NMPA approval...
Roche’s Fenebrutinib Hits Phase III Endpoint in MS – BTK Inhibitor Cuts Relapse Rate 51% vs. Standard of Care
Roche (SWX: ROG, OTCMKTS: RHHBY) announced that the pivotal Phase III FENhance 1 study for fenebrutinib in relapsing...
SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal
SanegeneBio, a Suzhou‑based RNA interference (RNAi) therapeutics developer, announced a global partnership with Genentech, a...
Roche Reports 7% Sales Growth to CHF 61.5B, Driven by Pharma and China
Roche (SWX: ROG, OTCMKTS: RHHBY) reported full‑year 2025 sales of CHF 61.5 billion : (USD 69.1 billion), representing 7% growth at...
Roche CT-388 Obesity Drug Shows 22.5% Weight Loss in Phase II Trial
Roche (SWX: ROG, OTCMKTS: RHHBY) announced positive topline results from its Phase II clinical trial (CT388‑103)...
MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal
MediLink Therapeutics announced a collaboration and exclusive licensing agreement with Roche (SWX: ROG, OTCMKTS: RHHBY)...
Roche cobas-liat Whooping-Cough Test Secures FDA Clearance
Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its cobas liat system-based point‑of‑care test for whooping...
Roche’s Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma
Roche Holding AG (SWX: ROG, OTCMKTS: RHHBY) announced that the European Commission (EC) has granted...
Roche’s giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial
Roche (SWX: ROG, OTCMKTS: RHHBY) announced its investigational oral SERD giredestrant met the primary endpoint...
Roche Announces Positive Phase III Results for Fenebrutinib in Relapsing & Primary‑Progressive Multiple Sclerosis
Roche Holding AG (SWX: ROG, OTCMKTS: RHHBY) reported that both pivotal Phase III trials of its...
Roche Announces a $55 M Partnership with Manifold Bio to Build BBB Shuttles
Swiss‑listed pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) confirmed a strategic alliance with platform biotech...
Roche Reports 7 % YoY Revenue Growth Through Q3 2025, Raises Full‑Year Guidance
Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its global group revenues grew 7 % year‑on‑year (YoY)...
Hansoh Pharma Grants Roche Exclusive Global Rights to CDH17‑Targeting ADC HS‑20110
Hansoh Pharmaceutical Group (HKG: 3692) today announced a licensing agreement with Roche (SWX: ROG, OTCMKTS:...
Roche Secures FDA Approval for Tecentriq‑Lurbinectedin Combo in ES‑SCLC
Roche (SWX: ROG, OTCMKTS: RHHBY) announced today that the U.S. Food and Drug Administration (FDA)...
Roche’s SC Lunsumio Gains CHMP Recommendation for Relapsed Follicular Lymphoma
Roche (SWX: ROG, OTCMKTS: RHHBY) announced that the European Medicines Agency’s Committee for Medicinal Products...
Roche’s giredestrant Yields Positive PFS Results in evERA Phase III Study
Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Phase III evERA trial has met both co‑primary...
Roche Announces $2.4 B Acquisition of 89bio, Targeting Liver and Cardiometabolic Therapies
Roche (SWX: ROG, OTCMKTS: RHHBY) announced today that it will acquire 89bio, Inc. (NASDAQ: ETNB)...